TY - JOUR
T1 - The risk of biopsy-detectable prostate cancer using the prostate cancer prevention trial risk calculator in a community setting
AU - Liang, Yuanyuan
AU - Ankerst, Donna P.
AU - Feng, Ziding
AU - Fu, Rong
AU - Stanford, Janet L.
AU - Thompson, Ian M.
PY - 2013/11
Y1 - 2013/11
N2 - Materials and methods: Risks of prostate cancer (CaP) and high-grade CaP were evaluated using the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) in an age-stratified random sample of 1,021 Caucasian and African-American men with no previous diagnosis of CaP, aged 55-74 years, residing in King County, WA, USA. Results: Median PCPTRC risks of CaP (high-grade CaP) were 15.6% (1.2%), 18.7% (2.0%), 18.5% (2.2%), and 26.4% (5.1%) for 55-59, 60-64, 65-69, and 70-74-year-old men, respectively; 25.2% of men aged 55-59 had a 25% or greater PCPTRC risk of CaP; this increased to 53.1% in men aged 70-74; 9.4% of men aged 55-59 had a 6% or greater PCPTRC risk of high-grade CaP, increasing to 44.1% in men aged 70-74. Conclusions: PCPTRC risk of CaP in a community of US males is high and confounded with overdetected cancers. In contrast, average community PCPTRC risk of high-grade disease is low and increases gradually by age and may better serve for counseling purposes.
AB - Materials and methods: Risks of prostate cancer (CaP) and high-grade CaP were evaluated using the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) in an age-stratified random sample of 1,021 Caucasian and African-American men with no previous diagnosis of CaP, aged 55-74 years, residing in King County, WA, USA. Results: Median PCPTRC risks of CaP (high-grade CaP) were 15.6% (1.2%), 18.7% (2.0%), 18.5% (2.2%), and 26.4% (5.1%) for 55-59, 60-64, 65-69, and 70-74-year-old men, respectively; 25.2% of men aged 55-59 had a 25% or greater PCPTRC risk of CaP; this increased to 53.1% in men aged 70-74; 9.4% of men aged 55-59 had a 6% or greater PCPTRC risk of high-grade CaP, increasing to 44.1% in men aged 70-74. Conclusions: PCPTRC risk of CaP in a community of US males is high and confounded with overdetected cancers. In contrast, average community PCPTRC risk of high-grade disease is low and increases gradually by age and may better serve for counseling purposes.
KW - High-grade prostate cancer
KW - Prostate Cancer Prevention Trial Risk Calculator (PCPTRC)
KW - Prostate cancer
KW - Prostate specific antigen (PSA)
UR - http://www.scopus.com/inward/record.url?scp=84886295532&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2012.03.012
DO - 10.1016/j.urolonc.2012.03.012
M3 - Article
C2 - 22552047
AN - SCOPUS:84886295532
SN - 1078-1439
VL - 31
SP - 1464
EP - 1469
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 8
ER -